Recently, it was reported that 5-azacitidine (5-AZA) administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia [3]. This evidence concerns the gene MS4A1 and B-cell acute lymphoblastic leukemia.